Evidence map›Paper›PMID 24886334›Full record

ArticleVeterinary research2014

The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to alcelaphine herpesvirus-1-mediated malignant catarrhal fever in cattle.

Nevi Parameswaran, George C Russell, Kathryn Bartley, Dawn M Grant, David Deane, Helen Todd, Mark P Dagleish, David M Haig

Open access · goldAbstract read
In one paragraph

Article in Veterinary research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nevi Parameswaran
George C Russell
Kathryn Bartley
Dawn M Grant
David Deane
Helen Todd
Mark P Dagleish
David M HaigSchool of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, LE12 5RD Nottingham, UK. david.haig@nottingham.ac.uk.
Moredun Research Institute · GBUniversity of Nottingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/H008950/1Biotechnology and Biological Sciences Research Council BB/H009116/1
6 · The paper itself

Abstract

We wished to determine the effect of of CpG ODN adjuvant on the magnitude and duration of protective immunity against alcelaphine herpesvirus-1 (AlHV-1) malignant catarrhal fever (MCF), a fatal lymphoproliferative disease of cattle. Immunity was associated with a mucosal barrier of virus-neutralising antibody. The results showed that CpG ODN included either with emulsigen adjuvant and attenuated AlHV-1 (atAlHV-1) or alone with atAlHV-1 did not affect the overall protection from clinical disease or duration of immunity achieved using emulsigen and atAlHV-1. This is in contrast to other similar studies in cattle with BoHV-1 or cattle and pigs with various other immunogens. In addition to this, several other novel observations were made, not reported previously. Firstly, we were able to statistically verify that vaccine protection against MCF was associated with virus-neutralising antibodies (nAbs) in nasal secretions but was not associated with antibodies in blood plasma, nor with total virus-specific antibody (tAb) titres in either nasal secretions or blood plasma. Furthermore, CpG ODN alone as adjuvant did not support the generation of virus-neutralising antibodies. Secondly, there was a significant boost in tAb in animals with MCF comparing titres before and after challenge. This was not seen with protected animals. Finally, there was a strong IFN-γ response in animals with emulsigen and atAlHV-1 immunisation, as measured by IFN-γ secreting PBMC in culture (and a lack of IL-4) that was not affected by the inclusion of CpG ODN. This suggests that nAbs at the oro-nasal-pharyngeal region are important in protection against AlHV-1 MCF.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralCattleCattle DiseasesEnzyme-Linked Immunosorbent AssayGammaherpesvirinaeHerpesviridae InfectionsImmunity, ActiveMaleMalignant CatarrhMethylationNoseOligodeoxyribonucleotidesToll-Like Receptor 9Vaccines, AttenuatedAdjuvants, ImmunologicAntibodies, ViralCPG-oligonucleotideOligodeoxyribonucleotidesToll-Like Receptor 9Vaccines, AttenuatedViral Vaccines

Identifiers

PMID24886334
PMCPMC4059458
OpenAlexW2108313452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.